Vaccines and Global Health: The Week in Review :: 23 April 2022

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to

– pdf version A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

World Immunization Week 2022 :: 24 – 30 April 2022

World Immunization Week 2022 :: 24 30 April 2022

World Immunization Week 2022 – Long Life for All
World Immunization Week, celebrated in the last week of April, aims to highlight the collective action

needed and to promote the use of vaccines to protect people of all ages against disease. WHO works with countries across the globe to raise awareness of the value of vaccines and

immunization and ensures that governments obtain the necessary guidance and technical support to implement high-quality immunization programmes. The ultimate goal of World Immunization Week is for more people – and their communities – to be protected from vaccine-preventable diseases.

This World Immunization Week 2022 campaign page will be updated regularly during World Immunization Week.

All resources can be downloaded in six languages and open design files here.

Over 1 million African children protected by first malaria vaccine

Over 1 million African children protected by first malaria vaccine

Ahead of World Malaria Day (25 April), WHO calls for continued innovation to save lives News release 21 April 2022

As World Malaria Day approaches, more than 1 million children in Ghana, Kenya and Malawi have received one or more doses of the world’s first malaria vaccine, thanks to a pilot programme coordinated by WHO. The malaria vaccine pilots, first launched by the Government of Malawi in April 2019, have shown that the RTS,S/AS01 (RTS,S) vaccine is safe and feasible to deliver, and that it substantially reduces deadly severe malaria.

These findings paved the way for the historic October 2021 WHO recommendation for the expanded use of RTS,S among children living in settings with moderate to high malaria transmission. If widely deployed, WHO estimates that the vaccine could save the lives of an additional 40 000 to 80 000 African children each year.

More than US$ 155 million has been secured from Gavi, the Vaccine Alliance to support the introduction, procurement and delivery of the malaria vaccine for Gavi-eligible countries in sub-Saharan Africa. WHO guidance is available to countries as they consider whether and how to adopt RTS,S as an additional tool to reduce child illness and deaths from malaria.

“As a malaria researcher in my early career, I dreamed of the day we would have an effective vaccine against this devastating disease,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This vaccine is not just a scientific breakthrough, it’s life-changing for families across Africa. It demonstrates the power of science and innovation for health. Even so, there is an urgent need to develop more and better tools to save lives and drive progress towards a malaria-free world.”

Prospects for new interventions

RTS,S is a first-generation vaccine that could be complemented in the future by other vaccines with similar or higher efficacy. WHO welcomes progress in the development of R21/Matrix-M and other malaria vaccine candidates in early clinical development. The successful completion of clinical trials for these vaccines will be important to assess their safety and efficacy profiles. WHO also welcomes the news from BioNTech, manufacturer of the Pfizer-BioNTech COVID-19 vaccine, that it aims to develop a malaria vaccine using mRNA technology.

In the field of vector control, a number of new tools and technologies have been submitted to WHO for evaluation. Should they demonstrate efficacy in controlling the disease, WHO will formulate new recommendations or amend existing ones to support their deployment. These include, for example, new types of insecticide-treated nets, spatial mosquito repellents, gene-drive approaches and sugar baits designed to attract and kill Anopheles mosquitoes.

There are also new medicines in the pipeline. WHO welcomes the recent approval by the Australian Therapeutic Goods Administration of dispersible tablets of single-dose tafenoquine for the prevention of P. vivax malaria among children. Tafenoquine has also been approved for use in adults by the US Federal Drug Administration and by drug regulatory bodies in other countries, including Brazil, Peru and Thailand. As a single dose, tafenoquine is expected to support patient adherence to treatment. The current standard of care requires a 7- or 14-day course of medication.

A number other antimalarial medicines with new modes of action are being developed for the treatment of uncomplicated and severe malaria. Ganaplacide-Lumefantrine, currently in a Phase II clinical trial, is the first non-artemisinin combination therapy and could be an asset in fight against emerging drug-resistant malaria in Africa.

In addition to drug resistance, WHO has reported other pressing threats in the fight against malaria, such as mosquito resistance to insecticides, an invasive malaria vector that thrives in urban and rural areas, and the emergence and spread of mutated P. falciparum parasites that are undermining the effectiveness of rapid diagnostic tests. Innovation in tools and strategies will be critical to contain these threats, together with a more strategic use of the tools that are available today…


:: See The Lancet editorial in in Journal Watch below ::

Child immunization programme reaches Rohingya refugee children on Bhasan Char island


Child immunization programme reaches Rohingya refugee children on Bhasan Char island

DHAKA, 21 April 2022 – This week, Rohingya refugee children on Bhasan Char in Bangladesh are receiving vaccinations through a routine childhood immunization programme.

UNICEF provides technical and financial assistance to the Government of Bangladesh in support of childhood immunizations on Bhasan Char. While Rohingya refugee children have received some vaccinations since arriving on the island through two ad hoc campaigns, this week marks the inauguration of the first regular childhood immunization programme on Bhasan Char…

“The routine childhood vaccination programme on Bhasan Char follows the Bangladesh Government’s national Expanded Programme on Immunization (EPI). This includes vaccinations against diphtheria, pertussis, tetanus, hepatitis-B, Hib, polio, pneumonia, tuberculosis, measles and rubella,” said Dr Md. Shamsul Haque, Line Director for Maternal Neonatal Child and Adolescent Health, Ministry of Health and Family Welfare. 

Rohingya refugee families began to be relocated from the refugee camps in Cox’s Bazar to the island of Bhasan Char just over a year ago. Estimations are that there are now well over 10,000 children on the island. UNICEF, UNHCR, WHO and other partners are working together to support the Government to deliver health and other services on Bhasan Char…

SAGE April 2022 meeting highlights – WHO

SAGE April 2022 meeting highlights – WHO
11 April 2022
SAGE Meeting of 4-7 April 2022
(Full report will be published in the Weekly Epidemiological Record on 10.06.2022, and only
the wording of the full report should be considered as final)


Session 1 – Global & Regional Reports
Report from the WHO Department of Immunization, Vaccines & Biologicals
• The speed of the COVID-19 vaccine rollout has been unprecedented with nearly every country
introducing the vaccine in under 12 months.
• Available data of COVID-19 vaccine effectiveness against the Omicron variant generally show
waning immunity against infection but high and more sustained effectiveness against severe
disease and death, especially after booster doses. Data remain very limited for some of the WHO
EUL vaccines.
• To date, 21 countries remain below 10% population coverage, leaving at high risk the most
vulnerable populations. Among countries eligible for support through the COVAX Advance
Market Commitment (AMC) strategy at least 43 have set population targets at 70% or higher
and only a small number have targets below 40% of their population.
• However, available data indicate that coverage among the high priority groups is insufficient to
provide the needed protection against severe disease and death. Health worker coverage is 65%
overall, with coverage below 50% in some regions (Non-AMC member states), and coverage of
older adults is 69% going as low as 24% in some regions.
• Disruptions to routine immunization programmes persist, including the ongoing delay of at least
one campaign in 37 countries as of 10 January 2022, putting millions of children at risk of disease
outbreaks. Large and disruptive outbreaks of measles have occurred in at least 19 countries
during the past 12 months.
• COVID-19 vaccination response and investments offer important opportunities that are being
leveraged to restore and strengthen immunization programmes and enhance their resilience.


WHO Regional Updates
• National immunization programmes in all six WHO regions were adversely impacted by the
COVID-19 pandemic through declining immunization coverage and surveillance quality, though
the magnitude of the impact varied between and within regions.
• The European region is also facing a challenge due to the ongoing war in Ukraine and the
resulting large population displacement. The WHO Regional Office and partner agencies are
taking measures to mitigate the risks of vaccine-preventable disease outbreaks such as measles,
polio, and COVID-19, while also ensuring continued delivery of critical medical supplies and
• All countries are implementing measures to restore vaccination coverage, with several having
identified innovative strategies for catch up vaccination.
• The rollout of COVID-19 vaccination is progressing in all regions, though vaccine uptake varies
between and within regions and disproportionately lower vaccination coverage has been
observed in low- and low-middle income countries. Vaccine hesitancy and low risk perception
are further affecting the uptake of COVID-19 vaccination in several countries.


Gavi report
• Reaching the zero-dose children through the building of resilient health systems remains a top
priority of the Alliance in the Gavi strategy 2021-2025 (Gavi 5.0) and is estimated to account for
over half the incremental impact of Gavi investments during the strategy period.
• A funding window for the rollout of malaria vaccines will be opened in the second half of 2022 to
enable initial vaccine introductions in 2023.
• Gavi expressed concern over the 13% decline of global HPV vaccine coverage in 2020 due to
COVID-19 disruptions, attributing this issue primarily to school closures and limited supply. It
was acknowledged that a recommendation for a single dose regimen has the potential to
accelerate introductions and reduce operational costs and complexity.
• The COVAX facility has sufficient supply available for all AMC countries to achieve the WHO 70%
coverage target by June 2022. The COVAX Vaccine Delivery Partnership is supporting countries
to overcome barriers and to achieve national coverage targets.


Session 2 – Immunization Agenda 2030 and catch-up vaccination
• SAGE was presented with evidence of the impact of the COVID-19 pandemic on national
immunization programmes mainly due to service delivery disruptions.
• The urgent need to close resulting immunity gaps was recognized, as was the importance of
supporting the recovery and resilience of immunization programmes and mitigating the risk of
vaccine-preventable disease outbreaks.
• SAGE recommended that countries use the COVID-19 pandemic and COVID-19 vaccination
rollout as a transformative opportunity to establish resilient immunization programmes and
strengthen primary health care. Among the specific areas identified were health worker
vaccination, immunization logistics and registries, surveillance, data and communications.
• The document “Guiding Principles for recovering, building resiliency, and strengthening of
immunization in 2022 and beyond” was endorsed and recommended for dissemination to
regional and national immunization technical advisory groups so that it may be adapted and
used for their local context.

[The full summaries for the sessions below are available at the PDF link above]
Session 3 – Hepatitis A vaccination


Session 4 – COVID-19 vaccines

Session 5 – Typhoid conjugate vaccination


Session 6 – Human Papillomavirus vaccination

Session 7 – Poliovirus vaccines



One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer
11 April 2022
News release
The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens.

SAGE’s review concluded that a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules.  This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls…

“The HPV vaccine is highly effective for the prevention of HPV serotypes 16 & 18, which cause 70% of cervical cancer,” said Dr Alejandro Cravioto, SAGE Chair. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.”


SAGE recommends updating dose schedules for HPV as follows:
one or two-dose schedule for the primary target of girls aged 9-14
one or two-dose schedule for young women aged 15-20
Two doses with a 6-month interval for women older than 21.

Immunocompromised individuals, including those with HIV, should receive three doses if feasible, and if not at least two doses. There is limited evidence regarding the efficacy of a single dose in this group.

WHO’s recommendations will be updated following further consultation across stakeholders…

Globally, the uptake of the life-saving vaccine has been slow, and coverage in countries much lower than the 90% target. Consequently, in 2020 global coverage with 2 doses was only 13%.  Several factors have influenced the slow uptake and low coverage of HPV vaccines including supply challenges, as well as the programmatic challenges and costs related to delivering a two regimen to older girls who are not typically part of childhood vaccination programs. Added to this has been the relatively high cost of HPV vaccines, particularly for middle-income countries…

The option for a single dose of the vaccine is less costly, less resource intensive and easier to administer. It facilitates implementing catch-up campaigns for multiple age groups, reduces the challenges link ed to tracing girls for their second dose and allows for financial and human resources to be redirected to other health priorities.”

COVID – IHR (2005 Emergency Committee)

COVID – IHR (2005 Emergency Committee)

Statement on the eleventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

13 April 2022

Statement  [Excerpts]

The eleventh meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) pandemic took place on Monday 11 April 2022…

The Secretariat presented on the current status of the COVID-19 pandemic and a vision for how to optimize the ongoing response to the COVID-19 pandemic  for 2022. The presentation focused on:

  • the global epidemiological context and factors that continue to drive transmission;
  • updates on international traffic as well as COVID-19 proof of vaccination and test result certificates;
  • the status of COVID-19 vaccination; and
  • the strategic objectives for countries to incorporate in their COVID-19 response.

The Committee discussed key issues including SARS-CoV-2 variants; use and equitable access to antivirals; vaccine protection and global shifts in the supply and demand for COVID-19 vaccines; hybrid immunity; potential future scenarios for SARS-CoV-2 transmission and challenges posed by concurrent health emergencies; and how Member States are responding to the COVID-19 pandemic. The Committee also noted with concern the growing fatigue among communities worldwide in response to the COVID-19 pandemic and challenges posed by the lack of trust in scientific guidance and governments….

The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses an ongoing risk of international spread and interference with international traffic, and requires a coordinated international response. The Committee stressed the importance for States Parties to prepare for future scenarios with the assistance of WHO and to continue robust use of the essential tools (e.g. vaccines, therapeutics, and diagnostics). The Committee concurred that the COVID-19 pandemic remains a PHEIC and offered its advice to the Director-General. 

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee and issued the Committee’s advice to States Parties as Temporary Recommendations under the IHR. 

The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work.

Equitable access to COVID-19 vaccination is a humanitarian imperative – ICRC

Equitable access to COVID-19 vaccination is a humanitarian imperative – ICRC

Statement by the International Committee of the Red Cross (ICRC) at the United Nations Security Council, New York 11 April 2022. Delivered by Dr. Esperanza Martinez, Senior Advisor to the Office of the Director-General

12-04-2022 | Statement

Mr. President, Members of the Council, Colleagues,

Thank you for the opportunity to address you today and to the UK for spotlighting the importance of vaccination in conflict settings through Resolution 2565 as well as continuing the Council’s focus on what needs to be done.

COVID-19 has killed more than 6 million people globally – with the number probably much higher as these are only the officially reported figures. The successes in the development and production of vaccines mean that many countries are starting to regain a sense of normalcy. However, to end the pandemic, vaccination needs to occur everywhere – and this is not the case in conflict-affected areas.

In conflict-settings, health systems torn apart by conflict are less able to contain the spread of diseases across frontlines and international borders. Vaccination and other health activities in such contexts are incredibly difficult to carry out. Furthermore, many people in conflict settings are overlooked in public health responses, including people displaced, detained, or living in areas controlled by non-state armed groups.

Moreover, in areas affected by armed conflict, COVID-19 is not the most pressing issue people face as the most basic needs – such as food, water, and shelter – are often not covered. Even if the health system continues to function, its focus turns from general health care, including vaccination, to treating war-wounded patients and keeping the core of the system functioning. This can happen in any conflict setting.

Mr. President,

The good news is that, as the supply of vaccine doses grows, the potential to get jabs in arms grows too. To achieve this in conflict settings, the International Committee of the Red Cross presents three asks to this Council, UN Member States, and conflict-affected countries:

First, ensure that International Humanitarian Law is respected

Under international humanitarian law, hospitals and other medical facilities as well as medical personnel – including those administering vaccines – are specifically protected from attacks. And where states cannot meet the basic needs of populations, they must allow impartial humanitarian organizations to conduct health activities – including vaccination.

These obligations are reaffirmed in Resolution 2565. We call on all parties to conflict to implement them in good faith as attacks on healthcare have a profound effect on people’s lives and future.

Second, integrate COVID-19 vaccinations into a broader health strategy and in tandem strengthen the health system

We have seen vaccines expire on airport tarmacs in Afghanistan, Nigeria, South Sudan, and several other places. Some of these vaccines were wasted because they arrived with too short expiry dates. Others, because the receiving countries’ health systems were not ready to distribute them. Countries need a degree of capacity to deliver vaccines.

The COVID-19 pandemic offers an opportune moment to strengthen the health systems in conflict-affected countries. We need to consider how COVID-19 vaccinations can be routinized where possible and integrated with other health services that are prioritized during times of conflict.

This doesn’t mean we have to do everything, but we must invest in country preparedness and fortify the building blocks of the health system that support immunizations – and which in turn support the response to other pre-existing health needs. Critically, this investment can help address renewed outbreaks of other highly contagious and lethal diseases – which are occurring today, for example with measles in Afghanistan and polio in the Democratic Republic of Congo.

One strategy to address this is to invest in developing health workers’ capacity and skillsets – as well as improving key components of service delivery, such as local supply chains and infrastructure. This is both critical and doable in contexts affected by armed conflict. The ICRC, for example, supported more than 600 health facilities in Iraq in 2021 which allowed the administration of over 14 million doses of COVID-19 vaccines.

Third, involve the community in vaccination activities and adequately resource community-engagement

Done well, effective community engagement is a force multiplier. It enhances the safety of frontline health workers and expands the reach of vaccination and other health efforts. Community involvement allows the community to identify pressing needs, take ownership, and spread the word about health-related programs.

For example, the ICRC established a network of Community Health Committees attached to 28 Primary Health Care Centres in Somalia and 16 in South Sudan. Many representatives are women from the community who can play an important role in the control and prevention of the COVID-19 pandemic and other diseases.

However, done poorly, ineffective or lack of community engagement can undermine public trust in vaccinations and government-run programs more broadly, with ramifications beyond this pandemic. We have witnessed the effects of distrust in West Africa with Ebola and now in many countries with COVID-19. Even if communities can be reached, people will not accept being vaccinated if they do not trust those administering the vaccine, and they do not see other pressing priorities being addressed.

For the ICRC and the wider Red Cross and Red Crescent Movement, community engagement ensures that communities’ insights are an integral part of the design and delivery of programs, and that people have accurate information about vaccines and public health interventions, so they can make informed choices for themselves. Beyond vaccination, the ICRC strives to build trust with communities and parties to conflict concerning all its humanitarian activities.

The ICRC – as part of the Red Cross and Red Crescent Movement – will continue to play its part.

The ICRC helped to administer more than 21 million doses of COVID-19 vaccines last year in areas impacted by armed conflict.

And we continue our offer of services to support states to implement their vaccination plans, to support National Red Cross and Red Crescent Societies as humanitarian auxiliaries, and to act as a neutral intermediary to facilitate access to vaccines and vaccination activities in hard-to-reach areas.

Equitable access to COVID-19 vaccination is a humanitarian imperative. Our collective recovery depends on it, because the longer COVID circulates anywhere, the longer it remains a threat everywhere.

“We must take the rapid action needed to accelerate vaccination.”


“We must take the rapid action needed to accelerate vaccination.”

COVID-19 Vaccine Delivery Partnership Global Lead Coordinator Ted Chaiban’s remarks at the Security Council briefing on equitable access to COVID-19 vaccines in conflict and humanitarian crises

Remarks   04/12/2022

As prepared.

   …“Just over 1 million cases of COVID-19 were reported to WHO in the last 24 hours – the pandemic is still far from over. We have safe and available vaccines that can protect against death and severe illness caused by COVID-19 and help avoid the next variant and there is an urgency, with over six million lives having been lost to date, to raise COVID-19 vaccination in countries that did not have this opportunity in 2021. The next six months are critical. 

“More than 11.1 billion doses of COVID-19 vaccines have been administered globally:

:: 124 of the 194 WHO member states have vaccinated more than 40% of their population

:: 51 countries have reached more than 70% of their population; only 11% in low-income countries.

:: 83% of the population in WHO’s Africa region and 51% in its Eastern Mediterranean region, which includes Afghanistan, remain unvaccinated.

“In 2022, we must take the rapid action needed to accelerate vaccination. The window of opportunity is gradually closing. We risk losing the momentum and failing on vaccine equity.

The COVID-19 Vaccine Delivery Partnership is focused, amongst others, on 34 countries which were at 10% or less full vaccine coverage and face the biggest challenges to increasing vaccination coverage. The goal is to vaccinate all adults and adolescents – starting with the elderly, healthcare and other frontline workers and those with underlying health conditions who are at the highest risk from COVID-19.

“19 of the 34 countries identified for concerted support by the Delivery Partnership are included in the Global Humanitarian Overview for 2022.

“We know there are many competing health, humanitarian and economic priorities in these countries. We must therefore use every opportunity to bundle or integrate COVID-19 vaccination with other health and humanitarian interventions and leverage these investments for the longer term strengthening of health systems.

“In many countries, COVID-19 vaccination is being integrated with measles campaigns and,in complement, with maternal health and routine immunization. COVID-19 vaccination is being used to strengthen cold chain, health management information systems and to train and provide incentives to health workers, including the surge required.

“With strong political leadership, country coordination and planning, and implementation of mass vaccination campaigns, countries can quickly pick up their vaccination rates and coverage. Since January 2022, the number of countries with a full population vaccination coverage rate at or below 10% has dropped from 34 countries to 18 countries currently…

…“I am speaking to you now from the Democratic Republic of the Congo where this week we will be meeting the government and key partners to better address the urgent bottlenecks to expanding vaccination coverage across this country of nearly 100 million people. We know Risk Communications and Community Engagement is a key component to success so we will be working with in-country partners to support clear communications to increase demand and work to improve convenient access to vaccination.

“In humanitarian settings, from Afghanistan to Yemen, addressing low vaccination rates requires integrating with humanitarian priorities, working with humanitarian partners and a sustained, country-by-country effort to identify and overcome the primary obstacles to increasing vaccination rates among the populations affected by natural disasters, conflict and socio-political instability. 

We recognize the significance of the Humanitarian Buffer, a mechanism established within the COVAX facility to ensure access to COVID-19 vaccines for high-risk and vulnerable populations living in humanitarian settings. As of today, two applicants have successfully received vaccine doses via the Humanitarian Buffer — the Ministries of Health in Iran and Uganda — but the partners are committed to make it a more user friendly, easily accessible mechanism to ensure that humanitarian populations not included in national vaccination plans, microplanning, or the implementation process can equally benefit from vaccination.

“The COVID-19 Vaccine Delivery Partnership and partners — UNICEF, WHO, GAVI, the World Bank, the Africa CDC and others — are providing concerted support to all these countries, mobilizing political engagement, providing flexible funding ($21 million in last two months), strategic advice and technical assistance. We are lining up partners behind one country team, one plan and one budget to put countries at the center and reduce their transaction costs. 

“Mr President, Excellencies, to address the significant vaccine equity gap that continues to pose a threat for global health security, please consider the following requests:

“First, continue your strong support and actions to implement Resolutions 2532 and 2565 with a particular focus on ensuring countries continue to prioritise COVID-19 vaccination.

“Second, with appreciation for the US$4.8 billion in pledges made at the COVAX AMC summit co-hosted with Germany, turn these commitments into support for lower-income countries’ COVID-19 vaccination needs, with a priority on delivery systems. Flexible, agile funding is vital and these investments can last beyond the pandemic.

“Third, advocate for and help guarantee full, safe and unhindered access, in line with International Humanitarian Law — including protecting humanitarian corridors — as a means to getting vital supplies of vaccines and other essential equipment for the delivery of COVID-19 vaccinations to populations in need and ensure the safety of health and humanitarian personnel administering vaccines in humanitarian settings.

“Fourth, advocate across government, and work with UN country teams and partners to ensure strong national vaccination planning that addresses the needs of all populations living within the national territory, regardless of nationality, migration or refugee status.

“Fifth, engage in the important conversations on the global health emergency architecture and advocate for strong governance and an investment in the basics of primary health care as a key element of future pandemic preparedness.”

WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

11 April 2022

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched on 11 April 2022 their new Trilateral COVID-19 Technical Assistance Platform. This new tool aims to help members and WTO accession candidates address their capacity building needs to respond to the COVID-19 pandemic.

In welcoming the initiative, WTO Director-General Okonjo-Iweala said the Platform “takes our trilateral collaboration to the next level: a one-stop shop for members to seek and receive support from the three organizations on all available tools including intellectual property flexibilities to improve access to COVID-19 vaccines, medicines, and related technologies.”

WHO Director-General Tedros Adhanom Ghebreyesus said: “The WHO-WIPO-WTO partnership aims to place public health innovation and intellectual property at the service of access to health technologies for everyone. Countries should consider using this platform and all other available mechanisms to promote public health.”

WIPO Director General Daren Tang noted the three organizations “came together last summer to offer our expertise and resources jointly to help members overcome the complex challenges posed by the pandemic. I am proud that through our partnership, we are providing a Trilateral Technical Assistance Platform that gives members a ‘one-stop shop’ access to the expertise and resources of all three organizations. By working together to support the strengthening of innovation, trade and health, we can help members overcome and recover.”

The new Platform for COVID-19 related technical assistance provides WTO members and accession candidates an overview of technical assistance activities offered by the three organizations.  It supports members and accession candidates seeking to address their needs for COVID-19 vaccines, medicines and related technologies and facilitates requests for the provision of timely and tailored technical assistance with a view to making full use of all available options…

COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain – IFPMA

COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain – IFPMA

  • To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live.
  • Several COVID-19 treatments are now standard of care for COVID-19. Biopharmaceutical companies with approved treatments are scaling up manufacturing capacity with wide use of voluntary licensing, but the effective roll out of treatments to all patients is dependent on swift regulatory approval, allocation strategies, health systems capacity, and testing.
  • The historic scaling up of manufacturing and the numerous technology transfers and voluntary licenses are further proof that intellectual property has been an enabler throughout the pandemic. Recent COVID-19 waves underscore that equitable access to vulnerable populations should be commanding all our collective efforts.

13 April 2022, Geneva – The COVID-19 pandemic continues to evolve and challenge the public health response. Meanwhile, the biopharmaceutical industry continues to bring its R&D expertise and solutions to the pandemic, while scaling up manufacturing of safe and effective treatments and vaccines. There is now broad acknowledgement that supplies of COVID-19 vaccines have outstripped demand, and manufacturing of treatments for people who have contracted COVID-19 or who are unable to be vaccinated is on track thanks, in part, to widescale voluntary licensing…

To date, 13.7 billion COVID-19 vaccine doses have been delivered[1]. While 11 billion COVID-19 vaccines have been administered thus far, equitable distribution remains a major concern. The spread of the Omicron BA2 variant underscores the importance of targeted immunization and should focus all minds to ensure full course vaccinations are administered with haste to all in need, in particular the elderly, vulnerable populations, and people who are immunosuppressed.

Sufficient vaccines are available to continue inoculation programs, since more than 7.98 billion doses could be produced this year. More than half of the doses forecast to be produced this year will be COVID-19 vaccines produced by companies member of IFPMA, together with partners who are in technology transfer agreements with them. In parallel to COVID-19 vaccine manufacturing, innovation into broader spectrum vaccines to tackle the pandemic continues apace, with combination vaccines or vaccines that are easier to transport and administer.

The biopharmaceutical industry remains steadfast in its position that steps urgently need to be taken to ensure all healthcare workers, the elderly, and those who are immunosuppressed or vulnerable through comorbidities wherever they live should receive a full course of vaccines. “The trend that we predicted last year that COVID-19 vaccine supplies will outstrip global demand has been proven correct,” said Thomas Cueni, Director General, IFPMA. The COVID-19 vaccine manufacturing scale-up has seen 372 partnerships forged, of which 88% (329) include technology transfer or fill & finish. 51 manufacturing and production agreements were made in developing countries (LICs and LMICs).

In addition, several important commitments have been made by biopharmaceutical companies that are set to change Africa’s vaccine manufacturing landscape in years to come. “To continue to advocate that vaccine equity is caused by scarcity of vaccines due to a lack of technology transfer flies in the face of the facts – both for the numbers of vaccines available but also for the way vaccines are made. The reasons for the woeful inequity are manyfold but cannot be laid at the door of intellectual property,” Cueni explained. “We remain steadfast in our verdict that the proposed World Trade Organization’s TRIPS waiver is a solution in search of a problem. It is a distraction and is misleading in its promise of equity for this pandemic. And it sends the wrong signal to innovators for future pandemics,” he concluded…

There is increasing acceptance that society will have to live with COVID-19. The vaccines and treatments that have been developed since the pandemic are essential public health tools to both alleviate the impact of the virus but also help people with other conditions access the care they need. Continued innovation remains essential. Fortunately, there is a strong pipeline for both COVID-19 vaccines and treatments, building on the 10 vaccines that have so far received WHO EUL approval[2] and the 18 different treatments that have been approved in the UK, USA, and EU.

Further innovation is critical to keep pace with the evolving nature of COVID-19. Today, there are 271 vaccines in preclinical and 147 in clinical phases and there are 1827 treatment candidates in clinical trials. Innovation is not without its risks; for example, so far 9 vaccine candidates that reached the final phase of clinical trials have been discontinued and 6 applications were rejected.



COVAX Guidance, Analysis, Reports

COVAX Guidance, Analysis, Reports

Emergency use of unproven clinical interventions outside clinical trials: ethical considerations – WHO

12 April 2022 :: 60 pages


This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with:

an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework), general and operational recommendations for implementing the framework and • answers to questions that stakeholders may raise.

Equitable access to COVID-19 tools – WHO

Aligning the private sector with national response efforts

12 April 2022 :: 28 pages


COVID-19 has reinforced the need for whole-of-society and whole-of-government approaches to the pandemic response. This has tested the foundation of public and private sector relations in healthcare, and either nurtured or exacerbated trust. In many instances, the private sector has demonstrated solidarity and delivered critical essential and COVID-19-related health services and products. However adverse behaviours have also featured. These have exacerbated the State’s duty to ‘protect’ the right to health, improve health security and system resilience for universal health care. The pandemic has further exposed the need for robust governance of health systems. This is good for both the private and public sectors, but most importantly, consumers, including those most likely to be left behind. This rapid review seeks to understand why and where there has been swift and proactive action to build better governance of national COVID-19 response, to cross-countries lessons sharing on how to govern the private sector in health to maximize the COVID-19


Coronavirus [COVID-19] – WHO Public Health Emergency of International Concern (PHEIC)



Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)


Weekly Epidemiological and Operational updates
Last update: 14 Apr 2022
Confirmed cases :: 500 186 525
Confirmed deaths :: 6 190 349
Vaccine doses administered: 11 294 502 059



Weekly epidemiological update on COVID-19 – 12 April 2022

Globally, during the week of 4 through 10 April 2022, the number of new COVID-19 cases has continued to decline for the third consecutive week, with a 24% decrease as compared to the previous week. Also the number of new weekly deaths continue the decreasing trend (-18% as compared to the previous week).
Across the six WHO regions, over 7 million cases and over 22 000 deaths were reported, with all the regions showing decreasing trends both in the number of new weekly cases and new weekly deaths.
As of 10 April 2022, over 496 million confirmed cases and over 6 million deaths have been reported globally.
In this edition we provide:
Special Focus: Update on WHO COVID-19 global rapid risk assessment
Updates on circulating SARS-CoV-2 variants of concern (VOCs), including information on Omicron descendent lineages.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022
[New additions; Full scale view available at title link above]
[Updated on 23 Apr 2022]


COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]


Press ReleasesNo new digest announcements identified

Bharat Biotech
Press Releases No new company announcements identified

BioCubaFarma – Cuba
Últimas Noticias – Website not leading at inquiry


Biological E
NewsNo new digest announcements identified


Press Releases
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
14 April 2022

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
11 April 2022


News – Website not responding at inquiry


Latest NewsNo new digest announcements identified


Recent NewsNo new digest announcements identified

Clover Biopharmaceuticals – China
NewsNo new digest announcements identified


Curevac [Bayer Ag – Germany]
April 11, 2022
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness


Gamaleya National Center
Latest News and Events – See Russia below.

Home – Website not responding at inquiry


Press Releases – No new digest announcements identified


Media – No new digest announcements identified


Press Releases
11 April, 2022
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates


News – No new digest announcements identified


Press Releases
Apr 13, 2022
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine


Recent Press Releases
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age


[No news or media page identified]


Sanofi Pasteur
Press Releases – No new digest announcements identified


Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

Shifa Pharmed [Iran]
No news page identified.


News – No new digest announcements identified


Press Releases – No new digest announcements identified


Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified


WestVac Biopharma
Media – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]



Press releases for media – No new digest announcements identified


News releases
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
April 14, 2022


News – No new digest announcements identified


SK Biosciences
Press releases
SK bioscience Initiates Clinical Development of Antiviral Nasal Spray for Prevention of COVID-19
SK began developing an innovative technology to prevent viral infections and relieve symptoms through intranasal spray
The spray is expected to be used as the first line of defense to prevent virus spread before vaccine development
The project is being funded by the Bill & Melinda Gates Foundation through a grant to IAVI and a subgrant to SK bioscience


Press Releases
April 14, 2022
Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine

COVID-19 Global Targets and Progress Tracker – IMF

COVID-19 Global Targets and Progress Tracker – IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Global Dashboard on COVID-19 Vaccine Equity

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 23 Apr 2022]:
See also visualization on Vaccine Access and Vaccine Affordability

The Race for Global COVID-19 Vaccine Equity

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

COVID-19 Data Explorer: Global Humanitarian Operations

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
23 Apr 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 500M total confirmed cases; 6.2M total confirmed deaths
Global vaccines administered: 11.4B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 280M
Other Delivered (Number of Doses): 260M
Total Delivered (Number of Doses): 540M
Total Administered (Number of Doses): 390M

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment



No new digest content identified.


BARDA-ASPR – U.S. Department of HHS [to 23 Apr 2022]
Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic
Tuesday, April 12, 2022





Press Announcements

FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials
Agency’s Focus on Inclusion in Trials for All Medical Products Aligns with Biden Administration’s Cancer Moonshot Goal of Addressing Inequities and Beyond
April 13, 2022
Today, the U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials –  expanding on the agency’s previous guidances for industry to improve clinical trial diversity.

“The U.S. population has become increasingly diverse, and ensuring meaningful representation of racial and ethnic minorities in clinical trials for regulated medical products is fundamental to public health,” said FDA Commissioner Robert M. Califf, M.D. “Going forward, achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities. This guidance also further demonstrates how we support the Administration’s Cancer Moonshot goal of addressing inequities in cancer care, helping to ensure that every community in America has access to cutting-edge cancer diagnostics, therapeutics and clinical trials.”

Despite having a disproportionate burden for certain diseases, racial and ethnic minorities are frequently underrepresented in biomedical research. Clinical trials provide a crucial base of evidence for evaluating whether a medical product is safe and effective; therefore, enrollment in clinical trials should reflect the diversity of the population that is ultimately going to use the treatment. It is known that biological differences exist in how people respond to certain therapies. For example, variations in genetic coding can make a treatment more or less toxic for one racial or ethnic group than another. These variations can also make drugs like antidepressants and blood-pressure medications less effective for certain groups.

This draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials,” recommends that sponsors of medical products develop and submit a Race and Ethnicity Diversity Plan to the agency early in clinical development, based on a framework outlined in the guidance…

Regulatory Actions
Vaccines and Related Biological Products Advisory Committee– FDA
No new calendar dates identified.





White House [U.S.] [to 23 Apr 2022]
Briefing Room – Selected Major COVID Announcements
Press Statement – COVID Context
No new digest content identified.


U.S. Department of State [to 23 Apr 2022]
Press Statement – COVID Context
No new digest content identified.


USAID [to 23 Apr 2022]
Selected Press Releases, Statements, Announcements
USAID Announces New Programs to Protect Our Ocean
April 14, 2022
Press Release
The U.S. Agency for International Development (USAID) announced 24 initiatives to protect our ocean at the Our Ocean Conference 2022 in Palau.

USAID Announces $18 Million Contribution to Education Cannot Wait
April 13, 2022
Press Release
The U.S. Agency for International Development (USAID) will contribute an additional $18 million to Education Cannot Wait (ECW), the major global fund for education in emergencies. USAID announced the additional funding during ECW’s scoping visit to Moldova to support the response to the crisis in Ukraine.

USAID and LIXIL Announce $10 Million to Confront the Global Sanitation Crisis
April 12, 2022
Today, the U.S. Agency for International Development and LIXIL, a global housing and sanitation products multinational company, launched the Partnership for Better Living to expand access to affordable sanitation and hygiene solutions for the underserved in up to 11 countries across sub-Saharan Africa and Asia by 2026.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment



European Medicines Agency
News & Press Releases
Press Releases
[No new digest content identified]





European Centre for Disease Prevention and Control
Latest Updates [Selected]
[No new digest content identified]




Accessed 23 Apr 2022





European Commission
Latest [Selected]
Press release 14 April 2022
Green Deal: EU announces €1 billion worth of commitments to protect the ocean
Today, at the Our Ocean Conference (OOC) in Palau, the EU has renewed its pledges towards international Ocean governance.

Press release 12 April 2022
Ukraine: EU humanitarian operation in the Republic of Moldova enhances assistance for refugees
Since the start of Russia’s invasion on 24 February, the refugee influx of civilians fleeing Ukraine to reach neighbouring countries has resulted in skyrocketing humanitarian needs.

Press release 9 April 2022
Stand Up For Ukraine: €9.1 billion pledged in support of internally displaced and refugees
The “Stand Up for Ukraine” global pledging event and campaign has raised €9.1 billion for people fleeing the Russian invasion, inside Ukraine and abroad, including €1 billion from the European Commission.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment



Ministry of Health and Family Welfare



Government of India – Press Information Bureau
Latest Press Releases
COVID – 19 Vaccination Update – Day 456
:: India’s cumulative vaccination coverage crosses 186.49 Crore
:: More than 11 lakh Vaccine doses administered today till 7 pm
:: More than 2.42 Crore Vaccine Doses administered to 12-14 age group so far
Posted On: 16 APR 2022 8:05PM by PIB Delhi



Indian Council for Medical Research (ICMR)
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

China tightens controls as Shanghai reports record Covid cases
Japan urges local government to address business concerns as ongoing restrictions hit commerce
Reuters in Shanghai
Sat 23 Apr 2022 10.42 EDT
Shanghai reported a record number of symptomatic Covid-19 cases on Saturday and other areas across China tightened controls as the country kept up its “dynamic clearance” approach that aims to stamp out the highly transmissible Omicron variant.

The Zhengzhou airport economic zone, a central Chinese manufacturing area that includes Apple supplier Foxconn, announced a 14-day lockdown on Friday “to be adjusted according to the epidemic situation”…

…Shanghai itself, which is at the centre of China’s recent Covid surge starting in early March, reported a record 3,590 symptomatic cases for 15 April, as well as 19,923 asymptomatic cases. The asymptomatic case number was up slightly from 19,872 cases a day earlier.

The city’s case tally makes up the vast majority of cases nationwide even as most of its 25 million residents remain under lockdown…

At the Zhengzhou economic zone, only personnel with valid passes, health codes and proof of negative Covid tests would be able to leave during the two-week period, although “special vehicles” would be able to travel normally for work reasons, local authorities said in a post on an official WeChat instant messaging account.

Overall, China reported 24,791 new coronavirus cases on 15 April, of which 3,896 were symptomatic and 20,895 were asymptomatic, the National Health Commission said on Saturday.

UN OCHA – Current Emergencies

UN OCHA – Current Emergencies
Current Corporate Emergencies
No new updates identified.


Northern Ethiopia
Ethiopia – Northern Ethiopia Humanitarian Update Situation Report, 14 Apr 2022
Humanitarian partners have not been able to move any additional aid supplies into Tigray by road since the convoy entered on 1 and 2 April.
About 36 metric tons of HIV medical supplies were airlifted to Mekelle, the first time since July 2021. It will be enough to provide treatment for 46,000 patients for six months.
Authorities in Amhara relocated more than 20,000 people out of the planned 70,000 people in North Wello and Wag Hamra zones to new designated sites since mid-March.
WFP assisted over 35,000 people with food in Gulina, Barahle and Dalole woredas in Afar during the reporting period, reaching over 235,000 people since last week of February.
More than 11,000 children under five and pregnant and lactating women received supplementary nutrients in Wag Harma and North Wello zones in Amhara between 1 and 10 April.

Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 15 April 2022)

WHO & Regional Offices [to 23 Apr 2022]

WHO & Regional Offices [to 23 Apr 2022]
News [Selected]
14 April 2022
Departmental news
The Global Diabetes Compact: a promising first year

14 April 2022
Departmental news
World Chagas Disease Day: finding and reporting every case

13 April 2022
Statement on the eleventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic
[See Milestones above for detail]

13 April 2022
Departmental news
Ukraine next country to receive technology from the WHO mRNA technology transfer hub

12 April 2022
Departmental news
Meeting of WHO Director-General’s Expert Group on Cervical Cancer Elimination, 19 April 2022

11 April 2022
Departmental news
SAGE April 2022 meeting highlights
[See Milestones above for detail]

11 April 2022
Departmental news
WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform

11 April 2022
News release
One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer
[See Milestones above for detail]


WHO Director General Speeches [selected]
14 April 2022
WHO Director-General’s opening remarks on Member State Information Session on COVID-19 – 14 April 2022

14 April 2022
WHO Director-General’s opening remarks at the Briefing to the African Union Ambassadors in Geneva on Strengthening Local Manufacturing Capacity – 14 April 2022

13 April 2022
WHO Director-General’s opening remarks at the WHO press conference – 13 April 2022

12 April 2022
WHO Director-General’s opening remarks at the International Strategic Dialogue on Noncommunicable Diseases and the Sustainable Development Goals – 12 April 2022

12 April 2022
WHO Director-General’s opening remarks at the Global Launch of the WHO QualityRights e-training to advance mental health, eliminate stigma and promote community inclusion  – 12 April 2022

12 April 2022
WHO Director-General’s opening remarks at the Public Hearing regarding a new international instrument on pandemic preparedness and response – 12 April 2022



WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: Africa witnesses longest-running decline in COVID-19 cases 14 April 2022
Brazzaville – Africa is experiencing its longest-running decline in COVID-19 infections since the onset of the pandemic. Recorded weekly cases have fallen for the past 16 weeks, while deaths have dropped for the last eight.
Infections—largely due to the Omicron-driven fourth pandemic wave—have tanked from a peak of over 308 000 cases weekly at the start of the year to less than 20 000 in the week ending on 10 April 2022. Over the past week, around 18 000 cases and 239 deaths were recorded, a decline of 29% and 37% respectively compared with the week before. This low level of infection has not been seen since April 2020 in the early stages of the pandemic in Africa…
:: Botswana, South Africa deepen probe into new Omicron sub-variants 12 April 2022
Brazzaville – Researchers in Botswana and South Africa have detected new sub-lineages of the Omicron variant of the SARS-CoV-2 and are carrying out further investigations to fully understand crucial traits such as infectivity and virulence.
The identified sub-lineages variant are BA.4 and BA.5. World Health Organization (WHO) experts are working with scientists and researchers in the two countries to deepen analysis of the sub-lineages which have so far been identified in four people in Botswana and 23 in South Africa. Outside Africa, the BA.4 and the BA.5 have been confirmed in Belgium, Denmark, Germany and the United Kingdom…
:: Deaths from noncommunicable diseases on the rise in Africa 11 April 2022
Accra/Brazzaville – Noncommunicable diseases such as cancer, cardiovascular diseases and diabetes are increasingly becoming the main cause of mortality in sub-Saharan Africa, where the diseases were responsible for 37% of deaths in 2019, rising from 24% in 2000 largely due to weaknesses in the implementation of critical control measures including prevention, diagnosis and care. This comes on the eve of a high-level heads of state and health leaders meeting in Ghana to find ways of accelerating progress against noncommunicable diseases…

WHO Region of the Americas PAHO
:: 13 Apr 2022
Less than 10% of those infected with Chagas disease receive timely diagnosis and treatment
PAHO calls for detection of all cases and equitable access to care for this disease, which causes about 30,000 new infections each year. Washington, DC, April 13, 2022 (PAHO)- Due to its silent nature, less than 10% of those infected with Chagas disease each year receive timely diagnosis and, therefore, effective treatment in Mexico, Central…
:: 11 Apr 2022
One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer
Geneva, 11 April 2022 (WHO)- The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens. SAGE’s review concluded that a single-dose Human Papillomavirus (HPV)…

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: Regional Director pledges WHO support to help Ukraine’s health system build back better during visit to Lviv 13-04-2022
:: Adjusting health financing for people fleeing conflict: WHO releases new guidance for countries in Europe 13-04-2022
:: ‘Ensuring high-quality of HIV Care for displaced people from Ukraine’ 13-04-2022
:: Novo Nordisk Foundation supports WHO’s emergency response in Ukraine and neighbouring countries with 25 million Danish kroner/3.4 million euros 13-04-2022

WHO Eastern Mediterranean Region EMRO
:: Taking the battle against malaria to its source – the mosquito 14 April 2022
:: WHO and KSrelief join efforts in the fight against child malnutrition in Yemen 13 April 2022
:: WHO delivers rapid antigen tests for COVID-19 to Iraq 11 April 2022

WHO Western Pacific Region
No new digest content identified.



Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
15 April 2022 | Circulating vaccine-derived poliovirus type 3 – Israel


15 April 2022 | Acute hepatitis of unknown aetiology – the United Kingdom of Great Britain and Northern Ireland



WHO Events
WHO Public Health Laboratories knowledge sharing webinars – Genomic surveillance and building up Next Generation Sequencing capacity
20 April 2022 11:00 – 12:30 CET


World Immunization Week
World Immunization Week 2022 – Long Life for All
24 – 30 April 2022


World Malaria Day 2022 – Harness innovation to reduce the malaria disease burden and save lives
25 April 2022


10th ACT-Accelerator Facilitation Council meeting
26 April 2022 12:30 – 15:00 CET



New WHO Publications
Selected Titles
14 April 2022
Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance
Routine diagnostic surveillance for COVID-19 has been augmented with environmental surveillance (ES) in wastewater in many locations. ES provides additional evidence on virus in circulation at population level including presence or absence, early warning of increasing or decreasing trends, and information on variants of concern or interest.
This guidance provides advice on:
What situations ES has been shown to add value to public health decision making
What is needed to plan and coordinate an effective ES programme
How to carry out data collection, analysis, interpretation and communication of results.
This guidance is targeted at public health officials who want to understand and integrate complementary ES into COVID-19 control strategies.

14 April 2022
Emergency in Ukraine: external situation report #7, published 14 April 2022: reporting period: 7–13 April…

13 April 2022
INSPIRE: seven strategies for ending violence against children: uptake between 2016 and 2021

13 April 2022
Health system performance assessment

12 April 2022
Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis…

12 April 2022
WHO Expert Committee on Biological Standardization: seventy-fourth report

12 April 2022
Emergency use of unproven clinical interventions outside clinical trials: ethical considerations
[See COVID above for detail]

12 April 2022
Ethics and medical radiological imaging: a policy brief for health-care providers

12 April 2022
Towards better engagement of the private sector in health service delivery

12 April 2022
Equitable access to COVID-19 tools
[See COVID above for detail]

11 April 2022
How to temperature map cold chain equipment and storage areas

11 April 2022
Noncommunicable Diseases Progress Monitor 2022

MMWR  Weekly: Current Volume (71) April 15, 2022 / No. 15

MMWR  Weekly: Current Volume (71) April 15, 2022 / No. 15
PDF of this issue
Surveillance to Track Progress Toward Polio Eradication — Worldwide, 2020–2021
COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022

Organization Announcements

Organization Announcements

Editor’s Note:

Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.


Airfinity    [to  23 Apr 2022]


Airfinity downgrades its global COVID-19 vaccine revenue forecast to $64.1B

Published by Airfinity

Apr 10, 2022

Airfinity has downgraded its global sales forecast for COVID-19 vaccines this year from $80.8bn to $64.1bn.



Paul G. Allen Frontiers Group    [to  23 Apr 2022]


No new digest content identified.


BMGF – Gates Foundation  [to  23 Apr 2022]

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute    [to  23 Apr 2022]

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people

No new digest content identified.

CARB-X   [to  23 Apr 2022]


No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation   [to  23 Apr 2022]


:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.

:: Informed Consent: A Monthly Review – April 2022 is now posted here

:: Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies – Invitation to Endorse

:: Patients, Politics, Pressure :: Pharma Stays Steady [Mostly] In Russia Sanctions Context

Observations at 30 March 2022     David R Curry

CEPI – Coalition for Epidemic Preparedness Innovations  [to  23 Apr 2022]

Latest News

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to  23 Apr 2022


No new digest content identified.

Duke Global Health Innovation Center  [to  23 Apr 2022]

Our Blog

No new digest content identified.



EDCTP    [to  23 Apr 2022]

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials


No new digest content identified.


Emory Vaccine Center    [to  23 Apr 2022]

Vaccine Center News

No new digest content identified.

European Vaccine Initiative  [to  23 Apr 2022]

Latest News, Events

No new digest content identified.



Evidence Aid   [to  23 Apr 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

New Resources

No new digest content identified.

Fondation Merieux  [to  23 Apr 2022]

News, Events

Mérieux Foundation & University of Geneva co-organized event

22nd Advanced Vaccinology Course (ADVAC)

May 9 – 20, 2022 – Les Pensières Center for Global Health, Veyrier-du-Lac (France)


Gavi [to  23 Apr 2022]

News Releases

No new digest content identified.

GHIT Fund   [to  23 Apr 2022]

Press Releases

No new digest content identified.


Global Fund  [to  23 Apr 2022]

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to  23 Apr 2022]


No new digest content identified

Hilleman Laboratories   [to  23 Apr 2022]

News & Insights

No new digest content identified



HHMI – Howard Hughes Medical Institute    [to  23 Apr 2022]

Press Room

No new digest content identified.


Human Vaccines Project   [to  23 Apr 2022]


No new digest content identified.



IAVI  [to  23 Apr 2022]

Latest News

No new digest content identified.



ICRC  [to  23 Apr 2022]

What’s New   [Selected]

ICRC Moscow Delegation: in brief

The delegation is one of our key humanitarian diplomacy hubs around the world, building dialogue with the Russian authorities, academic and expert circles, and other influential people and organizations in order to support our mission to protect and as

18-04-2022 | Publication

International Coalition of Medicines Regulatory Authorities [ICMRA]

Selected Statements, Press Releases, Research

No new digest content identified.


Press Releases/Announcements

No new digest content identified.

IFRC   [to  23 Apr 2022]

Press Releases [Selected]

Americas: IFRC urges governments to save migrants’ lives at High Level Regional Meeting on Migration

20/04/2022 | Press release

IFRC urges governments to save migrants’ lives, ensure their access to essential services and social inclusion mechanisms, and scale up support to persons at risk of displacement related to disasters and the climate crisis…

Institut Pasteur   [to  23 Apr 2022]

Press Documents

Press release


When severe infection causes long-term mood disorders: A promising avenue to prevent mental illness following a transient infection

The brain is able to detect and regulate localized or systemic inflammation by using two communication pathways.



IOM / International Organization for Migration [to  23 Apr 2022]

News – Selected


22 Apr 2022

Almost 1 Million War Displaced to Benefit from IOM Ukraine Shelter Rehabilitation Programme


21 Apr 2022

One in Six People Internally Displaced in Ukraine


19 Apr 2022

Ukraine: Remarks by IOM Director General, António Vitorino, at the UN Security Council  


ISC / International Science Council  [to  23 Apr 2022]

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News  Blogs  Podcasts  Events

News    Press releases

International science organizations unite in support of at-risk, displaced and refugee scientists


Join the advocacy campaign to support at-risk, displaced and refugee scientists by signing the Science in Exile Declaration.

IVAC  [to  23 Apr 2022]

Updates; Events

World Immunization Week 2022: Webinars

April 2022

During World Immunization Week 2022 the International Vaccine Access Center, along with global immunization and indigenous health partners, will host a three webinars. Registration is free, and we encourage all to sign up and save these dates on their calendars. Enabling Equitable Access to COVID-19 Vaccines for Indigenous Populations When: April 26, 2022 from 6:00 […]



IVI   [to  23 Apr 2022]

IVI News & Announcements

International Vaccine Institute appoints two members to its Board of Trustees representing Ecuador and Rwanda

April 20, 2022 – SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with the mission to discover, develop and deliver safe, effective and affordable vaccines for global health, announced today that Dr. Ximena Garzón Villalba, Minister of Public Health of Ecuador, and Dr. Leon Mutesa, Professor of Human Genetics at the University of Rwanda, will join its Board of Trustees (BOT), representing Ecuador and Rwanda, respectively, two member states of IVI. Their terms will commence at the next BOT meeting scheduled for May 19-20, 2022, in Stockholm, Sweden…



Johns Hopkins Center for Health Security   [to  23 Apr 2022]

Center News

No new digest content identified.



MSF/Médecins Sans Frontières  [to  23 Apr 2022]

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine – USA  [to  23 Apr 2022]

News [Selected]

NAM Statement on the Importance of Ensuring a Systems-Based Approach to Patient Safety and Quality

April 19, 2022

The recent case of a former nurse who was found guilty of negligent homicide after the death of a patient due to a medication error prompts the need to underscore the recommendations from To Err is Human: Building a Safer Health System. A core finding of To Err is Human is that medical errors are most often caused by failures […]

New National Academy of Medicine Consensus Study Launched on Improving Cross-Sectoral, Coordinated, and Equitable Governance of Emerging Technologies in Health and Medicine

April 15, 2022

An ad hoc committee under the auspices of the National Academies of Sciences, Engineering, and Medicine has been convened to develop a cross-sectoral governance framework for considering the potential benefits and risks that emerging science, technology, and innovation in health and medicine can bring to society. The framework will translate key ethics principles into the […]

National Academy of Sciences – USA  [to  23 Apr 2022]


American Chemical Society Joins U.S. National Academy of Sciences in Effort to Support Researchers Forced to Flee Ukraine

April 20, 2022

With a 500000 donation the American Chemical Society has joined the U.S. National Academy of Sciences in an effort to help researchers who are being forced to flee Ukraine because of Russia’s invasion.


National Vaccine Program Office – U.S. HHS  [to  23 Apr 2022]

Upcoming Meetings/Latest Updates                          

No new digest content identified.


NIH  [to  23 Apr 2022]

News Releases

Virtual Meeting and Listening Session on Oversight Framework for Research Involving Enhanced Potential Pandemic Pathogens

April 21, 2022 — Input from this listening session will help inform the deliberations and policy recommendations of the National Science Advisory Board for Biosecurity related to its current charge.



OECD  [to  23 Apr 2022]


No new digest content identified.


PATH  [to  23 Apr 2022]

Press Releases

PATH announces Dr. Fredrick Were as Vice Chair of the Board of Directors

April 21, 2022 by PATH

PATH is pleased to announce Dr. Fredrick Namenya Were, MD, MMed, PhD as Vice Chair of the board of directors. Dr. Were brings a unique mix of policy, research, and clinical experience to the leadership role. He has served on the board since March 2021 and is a member of the Governance, Impact, and Responsibility Committee…

PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi

April 19, 2022 by PATH

Seattle, April 19, 2022—PATH today welcomed a grant of close to US$ 5 million to enable expanded introduction of the RTS,S/AS01 (RTS,S) malaria vaccine through the pilot program currently underway in areas of Ghana, Kenya, and Malawi. The grant would support use of RTS,S in pilot areas that have not yet received the vaccine.

The grant to PATH was recommended by GiveWell, a US-based non-profit, for funding by Open Philanthropy, also based in the United States. The award will provide each pilot country with funds to plan for and implement the expansion of malaria vaccination through the end of 2023, the formal end of the pilot program. The grant also will allow PATH and the World Health Organization (WHO) to provide technical assistance to the countries. The vaccine doses for the expansion into the (currently) non-vaccinating pilot areas are part of GSK’s donation of up to 10 million doses for use in the pilot program…



Sabin Vaccine Institute  [to  23 Apr 2022]

Statements and Press Releases

No new digest content identified.

UNAIDS [to  23 Apr 2022]

Selected Press Releases/Reports/Statements

22 April 2022

Sustaining HIV services for people who use drugs in Odesa

21 April 2022

Welcoming Ukrainian refugees in Germany: big test for all

20 April 2022

Social entrepreneurship—a tool of self-empowerment for the LGBTI community


UNHCR Office of the United Nations High Commissioner for Refugees [to  23 Apr 2022]

Selected News Releases, Announcements

No new digest content identified.

UNICEF  [to  23 Apr 2022]

Press Releases, News Notes, Statements  [Selected]

Press release


At least 10 million children face severe drought in the Horn of Africa – UNICEF

NAIROBI, 22 April 2022 – The number of children facing severe drought conditions across the Horn of Africa has increased by more than 40 per cent in the space of two months, warns UNICEF.  Between February and April, the number of children facing the impact of drought including acute hunger, malnutrition and thirst increased from 7.25 million to…

Press release


Child immunization programme reaches Rohingya refugee children on Bhasan Char island

DHAKA, 21 April 2022 – This week, Rohingya refugee children on Bhasan Char in Bangladesh are receiving vaccinations through a routine childhood immunization programme. UNICEF provides technical and financial assistance to the Government of Bangladesh in support of childhood immunizations on Bhasan Char. While Rohingya refugee children have…

[See Perspectives above for detail]

Press release


Lebanon’s crisis threatening children’s health

BEIRUT, 20 April 2022 ­ – The ripple effects of the global economic situation – with heightened prices and increased inflation – are exacerbating Lebanon’s calamitous crisis, with grave consequences for children’s health, UNICEF said in a report released to coincide with World Immunization Week (WIW). This will cause more disruptions in the health…



Statement by UNICEF Executive Director Catherine Russell on attacks against schools in Kabul, Afghanistan

NEW YORK, 19 April 2022 – “I am horrified by the brutal attacks targeting school children today in western Kabul, Afghanistan. The coordinated blasts occurred at the Mumtaz Tuition Center and Abdul Raheem Shaheed High School. “Reports are still being verified, but at least nine children are believed to have been killed and more than fifty injured…

Press release


Sana’a authorities in Yemen sign action plan with UN to prevent grave violations against children

SANA’A, 18 April 2022 – Today Sana’a authorities signed an Action Plan with the United Nations to protect children and prevent grave violations against them in the context of the armed conflict in Yemen. The Action Plan commits the Sana’a authorities and their forces to comply with the prohibition of the recruitment and use of all children in…


Unitaid  [to  23 Apr 2022]

Featured News

22 April 2022

World Malaria Day: Unitaid drives forward equitable access to innovation to reduce the burden of malaria

Vaccine Equity Cooperative [nee Initiative]   [to  23 Apr 2022]


No new digest content identified.



Vaccination Acceptance & Demand Initiative [Sabin)  [to  23 Apr 2022]

Announcements, Blog


Keeping Vaccination in the Conversation

April 18, 2022

by: Meredith Dockery, Nick Boehman, Abigail Quinn



Vaccine Confidence Project  [to  23 Apr 2022]

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to  23 Apr 2022]


No new digest content identified.

Wellcome Trust  [to  23 Apr 2022]

News. Opinion, Reports

No new digest content identified.

The Wistar Institute   [to  23 Apr 2022]

Press Releases

No new digest content identified.



WFPHA: World Federation of Public Health Associations  [to  23 Apr 2022]

Latest News – Blog

No new digest content identified.


World Bank [to  23 Apr 2022]

Selected News, Announcements

EVENT: Scaling up Vaccine Deployment

As global vaccine supplies increase, a key challenge is to ensure that supplies quickly get to where they are needed and, once they are there, countries have the capabilities and resources to get vaccines…

Date: April 28, 2022 Type: Feature Story



World Customs Organization – WCO  [to  23 Apr 2022]

Latest News

No new digest content identified.


World Organisation for Animal Health (OIE)   [to  23 Apr 2022]

Press Releases, Statements

Prevention is better than a cure: delivering quality vaccines to stop the spread of animal diseases

20 April 2022



WTO – World Trade Organisation [to  23 Apr 2022]

WTO News and Events [Selected]

Multilateralism “must be reimagined and fit for purpose,” DG tells Brazilian diplomats

18 April 2022

Brazil, and in particular its powerhouse agri-food sector, has benefited from open markets provided by the multilateral trading system, and it can benefit even more with a revitalized WTO, Director-General Ngozi Okonjo-Iweala told young diplomats and other guests at a lecture at Instituto Rio Branco, Brazil’s diplomatic academy, in Brasilia on 18 April. She stressed that multilateralism “must be reimagined and made fit for purpose to serve 21st century challenges”. The lecture opened a two-day visit for talks with government officials, the agriculture industry, parliamentarians and businesspeople. Her remarks are below.





ARM [Alliance for Regenerative Medicine]  [to  23 Apr 2022]

Selected Press Releases

No new digest content identified.



BIO    [to  23 Apr 2022]

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network  [to  23 Apr 2022]

News; Upcoming events

No new digest content identified.



ICBA – International Council of Biotechnology Associations   [to  23 Apr 2022]


No new digest content identified.



IFPMA   [to  23 Apr 2022]

Selected Press Releases, Statements, Publications

Joint Guidance on Virtual and Hybrid International Medical Congresses

13 April 2022

Joint Guidance on Virtual and Hybrid International Medical Congresses by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA)

:: Joint Guidance on Virtual and Hybrid International Medical Congresses (April 2022)

:: Joint Guidance on Virtual and Hybrid International Medical Congresses (April 2022) Q&A



International Generic and Biosimilar Medicines Association [IGBA]


No new digest content identified.



International Alliance of Patients’ Organizations – IAPO  [to  23 Apr 2022]

Press and media [Selected]

No new digest content identified.



PhRMA    [to  23 Apr 2022]

Latest News [Selected]

No new digest content identified.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at:

Health Equity in US Latinx Communities

AMA Journal of Ethics
Volume 24, Number 4: E249-341 Apr 2022


Health Equity in US Latinx Communities
Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia

BMC Health Services Research


(Accessed 23 Apr 2022)
Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia
People’s lives were seriously affected by the emergence and the spread of the COVID-19 disease. Several vaccines were developed in record time to overcome this pandemic. However, putting an end to this public …
Authors: Nawel Zammit, Amani El Gueder, Aïcha Brahem, Imen Ayouni, Rim Ghammam, Sihem Ben Fredj, Chaima Sridi, Asma Chouchene, Houda Kalboussi, Olfa El Maalel, Souhaeil Chatti, Jihene Maatoug, Hassen Ghannem and Néjib Mrizak
Citation: BMC Health Services Research 2022 22:489
Content type: Research Published on: 12 April 2022

Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease

BMC Infectious Diseases
(Accessed 23 Apr 2022)


Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease
The rapid worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections led to public health crises globally and the number of pediatric patients with Coronavirus Disease 2019 (CO…
Authors: Setareh Mamishi, Babak Pourakbari, Mehrzad Mehdizadeh, Amene Navaeian, Hamid Eshaghi, Bahareh Yaghmaei, Reihaneh Hosseinpour Sadeghi, Shiva Poormohammadi, Yasmine Mahmoudieh and Shima Mahmoudi
Citation: BMC Infectious Diseases 2022 22:382
Content type: Research article Published on: 15 April 2022

Determinants of measles vaccination dropout among 12 − 23  months aged children in pastoralist community of Afar, Ethiopia

BMC Infectious Diseases
(Accessed 23 Apr 2022)


Determinants of measles vaccination dropout among 12 − 23 months aged children in pastoralist community of Afar, Ethiopia
Measles is a viral disease and a leading vaccine-preventable childhood killer. More than 95% of measles deaths occur in countries with low incomes and weak health infrastructures. In response to this, Ethiopia…
Authors: Chekole Hailu, Girmatsion Fisseha and Aregawi Gebreyesus
Citation: BMC Infectious Diseases 2022 22:376
Content type: Research article Published on: 14 April 2022

Barriers to and strategies to address COVID-19 testing hesitancy: a rapid scoping review

BMC Public Health
(Accessed 23 Apr 2022)


Barriers to and strategies to address COVID-19 testing hesitancy: a rapid scoping review
Testing is a foundational component of any COVID-19 management strategy; however, emerging evidence suggests that barriers and hesitancy to COVID-19 testing may affect uptake or participation and often these a…
Authors: Mark Embrett, S. Meaghan Sim, Hilary A. T. Caldwell, Leah Boulos, Ziwa Yu, Gina Agarwal, Rhiannon Cooper, Allyson J. Gallant AJ, Iwona A. Bielska, Jawad Chishtie, Kathryn Stone, Janet Curran and Andrea Tricco
Citation: BMC Public Health 2022 22:750
Content type: Research Published on: 14 April 2022

Considering social inequalities in health in large-scale testing for COVID-19 in Montréal: a qualitative case study

BMC Public Health
(Accessed 23 Apr 2022)


Considering social inequalities in health in large-scale testing for COVID-19 in Montréal: a qualitative case study
Evidence continues to demonstrate that certain marginalised populations are disproportionately affected by COVID-19. While many studies document the impacts of COVID-19 on social inequalities in health, none h…
Authors: Marie-Catherine Gagnon-Dufresne, Lara Gautier, Camille Beaujoin, Ashley Savard Lamothe, Rachel Mikanagu, Patrick Cloos, Valéry Ridde and Kate Zinszer
Citation: BMC Public Health 2022 22:749
Content type: Research Published on: 14 April 2022

Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar

BMC Public Health
(Accessed 23 Apr 2022)


Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
While mass COVID-19 vaccination programs are underway in high-income countries, limited availability of doses has resulted in few vaccines administered in low and middle income countries (LMICs). The COVID-19 …
Authors: Fidisoa Rasambainarivo, Tanjona Ramiadantsoa, Antso Raherinandrasana, Santatra Randrianarisoa, Benjamin L. Rice, Michelle V. Evans, Benjamin Roche, Fidiniaina Mamy Randriatsarafara, Amy Wesolowski and Jessica C. Metcalf
Citation: BMC Public Health 2022 22:724
Content type: Research Published on: 12 April 2022

A network of change: united action on research integrity

BMC Research Notes
(Accessed 23 Apr 2022)


A network of change: united action on research integrity
Authors: Thomas Rhys Evans, Madeleine Pownall, Elizabeth Collins, Emma L. Henderson, Jade S. Pickering, Aoife O’Mahony, Mirela Zaneva, Matt Jaquiery and Tsvetomira Dumbalska
Citation: BMC Research Notes 2022 15:141
Content type: Commentary Published on: 14 April 2022
The last decade has seen renewed concern within the scientific community over the reproducibility and transparency of research findings. This paper outlines some of the various responsibilities of stakeholders in addressing the systemic issues that contribute to this concern. In particular, this paper asserts that a united, joined-up approach is needed, in which all stakeholders, including researchers, universities, funders, publishers, and governments, work together to set standards of research integrity and engender scientific progress and innovation. Using two developments as examples: the adoption of Registered Reports as a discrete initiative, and the use of open data as an ongoing norm change, we discuss the importance of collaboration across stakeholders.

Learning lessons from lipids to make COVID-19 vaccines

Apr 14, 2022 Volume 185 Issue 8 p1261-1444


Learning lessons from lipids to make COVID-19 vaccines
A game-changing intervention in the COVID-19 pandemic has been the rapid implementation of highly effective vaccines against SARS-CoV-2. The 2022 Canada Gairdner International Award recognizes Pieter Cullis, Katalin Karikó, and Drew Weissman “for their pioneering work developing nucleoside-modified mRNA and lipid nanoparticle (LNP) drug delivery: the foundational technologies for the highly effective COVID-19 mRNA vaccines.” Cell editor Cheri Sirois caught up with Pieter to discuss how a long interest in basic and applied questions in lipid biology led to this fortuitous collaboration. Excerpts of the conversation are presented below.

The voices of Ukrainian and Russian scientists

Apr 14, 2022 Volume 185 Issue 8 p1261-1444


The voices of Ukrainian and Russian scientists
Rostyslav Stoika, Nikita Gudimchuk, Halyna R. Shcherbata, Andrey Zaraisky, Oleksandr Shcheglovitov,
Yevgenia Kozorovitskiy, Viktor Korolchuk
The brutal attack on Ukraine by the Russian Federation has shocked the world. While the world works to end the violence and help refugees, as a scientific journal, our thoughts are also with those in the scientific community who are directly or indirectly impacted by the war. We have been inspired by and applaud the labs around the world that have opened their doors to displaced scientists and remain committed to supporting scientists, whoever and wherever they are. Because science requires collaboration and trust, we urge the scientific community to continue efforts like this and to remain united, especially in times as difficult as these. In this Voices piece, we feature short comments from scientists from Ukraine and scientists from Russia. This small sampling is far from exhaustive, but our sincere thanks go to those scientists who were willing to share their thoughts on this volatile and emotionally charged situation; the views expressed are those of the contributors alone. We join the world in hoping for a swift resolution to the conflict, for the good of humanity.

Therapeutic Innovations in Neuroscience

Clinical Pharmacology & Therapeutics
Volume 111, Issue 4 Pages: 705-971 April 2022


Therapeutic Innovations in Neuroscience
The theme of this issue of Clinical Pharmacology & Therapeutics (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

What is the impact of intellectual property rules on access to medicines? A systematic review

Globalization and Health
[Accessed 23 Apr 2022]


What is the impact of intellectual property rules on access to medicines? A systematic review
It is widely accepted that intellectual property legal requirements such as patents and data exclusivity can affect access to medicines, but to date there has not been a comprehensive review of the empirical e…
Authors: Brigitte Tenni, Hazel V. J. Moir, Belinda Townsend, Burcu Kilic, Anne-Maree Farrell, Tessa Keegel and Deborah Gleeson
Citation: Globalization and Health 2022 18:40
Content type: Review Published on: 15 April 2022

Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis

Journal of Infectious Diseases
Volume 225, Issue 4, 15 February 2022


Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysisGet access
Huizhi Gao, Eric H Y Lau, Benjamin J Cowling
The Journal of Infectious Diseases, Volume 225, Issue 4, 15 February 2022, Pages 557–566,
Our results supported the notion that secondary vaccine failure may be the reason for reemergence of pertussis and diphtheria. Tetanus and polio vaccines provided more sustained protection.